A $2.9 million grant will fund planned trials of a drug after immune-cell therapy for cancer that often returns
RedHill Biopharma (RDHL) announced a $2.9M grant for trials of its drug opaganib combined with CAR T-cell therapy for multiple myeloma. The University of Oklahoma will conduct the trials, with RedHill providing opaganib. Preclinical studies suggest the combination may improve treatment outcomes. Opaganib targets the SPHK2 protein, potentially enhancing immune cell activity against cancer.
How this was made
The 30-second read
Why it matters
The $2.9 M grant from the National Cancer Institute enables a five‑year preclinical/early clinical program, reducing cash‑flow pressure and signaling regulatory support.
Market read
While the funding amount is modest, it removes a financing hurdle for an early‑stage oncology program, offering a slight positive catalyst for RDHL.
What to watch
Potential competition from other CAR‑T programs and the need for substantial additional financing before late‑stage trials.
Background
RedHill Biopharma (RDHL) is developing opaganib, a first‑in‑class sphingosine‑kinase‑2 inhibitor, for multiple oncology and infectious disease indications.
Ticker impact
RedHill Biopharma received a $2.9 million grant to fund CAR‑T cell therapy trials with opaganib, marking the first public disclosure of this funding.
likely modest upside as investors price in potential trial progress and additional data milestones.
Grant size is modest and trial results are far off; however, the news removes funding uncertainty and may lift sentiment.
Market effects
Highlights continued interest in CAR‑T and sphingosine‑kinase inhibitors within oncology biotech.
May boost perception of US‑listed biotech funding pipelines.
Limited; primarily relevant to investors tracking early‑stage oncology therapeutics.
Counterpoint
The grant is small and far from commercial impact; investors may over‑react to a modest funding announcement.
Key entities
- partnerUniversity of Oklahoma
Research institution receiving the grant and hosting CAR‑T manufacturing.
- partnerLentigen Technology / Miltenyi Biotec
Provider of the lentiviral vector for CAR‑T cell production.
